RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi

Journal of Investigative Dermatology

Volumn 132, Issue 3 PART 1, 2012, Pages 687-694

  Helmbold, Peter ^a   Richter, Antje M ^b   Walesch, Sara ^b   Skorokhod, Alexander ^a   Marsch, Wolfgang Ch ^c   Enk, Alexander ^a   Dammann, Reinhard H ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RASSF10; PROTEIN RASSSF2; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; NEVUS CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION;

EID: 84857061730     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2011.380     Document Type: Article

References (41)

1. Allegrucci C, Wu YZ, Thurston A et al. (2007) Restriction landmark genome scanning identifies culture-induced DNA methylation instability in the human embryonic stem cell epigenome. Hum Mol Genet 16:1253-68 (Pubitemid 47062721)
2. Allen NP, Donninger H, Vos MD et al. (2007) RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 26:6203-11 (Pubitemid 47414375)
3. Antequera F, Boyes J, Bird A (1990) High levels of de novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 62: 503-14
4. Balch CM, Gershenwald JE, Soong S-j et al. (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-206
5. Cortvrindt R, Bernheim J, Buyssens N et al. (1987) 5-Azacytidine and 5-aza-20-deoxycytidine behave as different antineoplastic agents in B16 melanoma. Br J Cancer 56:261-5 (Pubitemid 17158813)
6. Dahl C, Guldberg P (2007) The genome and epigenome of malignant melanoma. APMIS 115:1161-76 (Pubitemid 350179478)
7. Dammann R, Li C, Yoon JH et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25:315-9 (Pubitemid 30437320)
8. Dammann R, Schagdarsurengin U, Liu L et al. (2003) Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22:3806-12 (Pubitemid 36760743)
9. Dammann R, Schagdarsurengin U, Seidel C et al. (2005) The tumor suppressor RASSF1A in human carcinogenesis: An update. Histol Histopathol 20:645-63 (Pubitemid 40468282)
10. Falvella FS, Manenti G, Spinola M et al. (2006) Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 25:3934-8 (Pubitemid 43990748)
11. Furuta J, Umebayashi Y, Miyamoto K et al. (2004) Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 95:962-8 (Pubitemid 40089588)
12. Hesson L, Dallol A, Minna JD et al. (2003) NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22:947-54 (Pubitemid 36255830)
13. Hesson LB, Dunwell TL, Cooper WN et al. (2009) The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 8:42
14. Hill VK, Underhill-Day N, Krex D et al. (2011) Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 30:978-89
15. Hoon DS, Spugnardi M, Kuo C et al. (2004) Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23:4014-22 (Pubitemid 38747930)
16. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-28 (Pubitemid 34587077)
17. Jones PA, Baylin SB (2007) The epigenomics of cancer. Cell 128:683-92 (Pubitemid 46273572)
18. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93 (Pubitemid 10117303)
19. Khokhlatchev A, Rabizadeh S, Xavier R et al. (2002) Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 12:253-65 (Pubitemid 34161469)
20. Klapperstuck T, Glanz D, Klapperstuck M et al. (2009) Methodological aspects of measuring absolute values of membrane potential in human cells by flow cytometry. Cytometry A 75:593-608
21. Lahtz C, Stranzenbach R, Fiedler E et al. (2010) Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 130:620-2
22. Miller AJ, Mihm MC Jr (2006) Melanoma. N Engl J Med 355:51-65
23. Parkin DM, Bray F, Ferlay J et al. (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108 (Pubitemid 40372904)
24. Rastetter M, Schagdarsurengin U, Lahtz C et al. (2007) Frequent intratumoural heterogeneity of promoter hypermethylation in malignant melanoma. Histol Histopathol 22:1005-15 (Pubitemid 47034166)
25. Reifenberger J, Knobbe CB, Sterzinger AA et al. (2004) Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 109:377-84 (Pubitemid 38252766)
26. Richter AM, Pfeifer GP, Dammann RH (2009) The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 1796:114-28
27. Richter AM, Schagdarsurengin U, Rastetter M et al. (2010) Protein kinase Amediated phosphorylation of the RASSF1A tumour suppressor at Serine 203 and regulation of RASSF1A function. Eur J Cancer 46:2986-95
28. Rothhammer T, Bosserhoff AK (2007) Epigenetic events in malignant melanoma. Pigment Cell Res 20:92-111 (Pubitemid 46439524)
29. Schagdarsurengin U, Gimm O, Dralle H et al. (2006) CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. Thyroid 16:633-42
30. Schagdarsurengin U, Richter AM, Hornung J et al. (2010) Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 9:264
31. Schagdarsurengin U, Richter AM, Wohler C et al. (2009) Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 4:571-6
32. Seliger B, Ritz U, Abele R et al. (2001) Immune escape of melanoma: First evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 61: 8647-50 (Pubitemid 34013870)
33. Sherwood V, Manbodh R, Sheppard C et al. (2008) RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 19:1772-82 (Pubitemid 351805128)
34. Spugnardi M, Tommasi S, Dammann R et al. (2003) Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 63:1639-43 (Pubitemid 36373656)
35. Steinmann K, Sandner A, Schagdarsurengin U et al. (2009) Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma. Oncol Rep 22:1519-26
36. Tellez CS, Shen L, Estecio MR et al. (2009) CpG island methylation profiling in human melanoma cell lines. Melanoma Res 19:146-55
37. Tommasi S, Dammann R, Jin SG et al. (2002) RASSF3 and NORE1: Identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21:2713-20 (Pubitemid 34478329)
38. Underhill-Day N, Hill V, Latif F (2011) N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 6:284-92
39. van der Weyden L, Adams DJ (2007) The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta 1776:58-85 (Pubitemid 47332074)
40. Vos MD, Ellis CA, Elam C et al. (2003) RASSF2 is a novel K-Rasspecific effector and potential tumor suppressor. J Biol Chem 278: 28045-51 (Pubitemid 36900001)
41. Xiong Z, Laird PW (1997) COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25:2532-4 (Pubitemid 27303718)